Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 28:9:2020-4-5.
doi: 10.7573/dic.2020-4-5. eCollection 2020.

Chloroquine and hydroxychloroquine in the context of COVID-19

Ashutosh M Shukla  1   2 , Lennox K Archibald  1   2 , Aparna Wagle Shukla  3 , Hiren J Mehta  2 , Kartikeya Cherabuddi  2
Affiliations
Review

Chloroquine and hydroxychloroquine in the context of COVID-19

Ashutosh M Shukla et al. Drugs Context. .

Abstract

Chloroquine and closely related structural analogs, employed initially for the treatment of malaria, are now gaining worldwide attention due to the rapidly spreading pandemic caused by severe acute respiratory syndrome-coronavirus-2, named coronavirus disease (COVID) of 2019 (COVID-19). Although much of this attention has a mechanistic basis, the hard efficacy data for chloroquine/hydroxychloroquine in the management of the clinical syndrome of COVID-19 have been limited thus far. This review aims to present the available in vitro and clinical data for the role of chloroquine/hydroxychloroquine in COVID-19 and attempts to put them into perspective, especially in relation to the different risks/benefits particular to each patient who may require treatment.

Keywords: COVID-19; SARS-CoV-2; anti-inflammatory; antimalarial; antiviral; chloroquine; hydroxychloroquine; immunomodulatory; pandemic.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/04/dic.2020-4-5-COI.pdf

Figures

Figure 1
Figure 1
Hypothetical immunological and antiviral model.
See this image and copyright information in PMC

References

    1. Shukla AM, Wagle Shukla A. Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. Drugs Context. 2019;8 doi: 10.7573/dic.2019-9-1. - DOI - PMC - PubMed
    1. Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70(6):1608–1621. doi: 10.1093/jac/dkv018. - DOI - PMC - PubMed
    1. Wallace DJ. The history of antimalarials. Lupus. 1996;5(Suppl 1):S2–3. - PubMed
    1. Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus. 1996;5(Suppl 1):S59–64. doi: 10.1177/0961203396005001131. - DOI - PubMed
    1. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–727. doi: 10.1016/s1473-3099(03)00806-5. - DOI - PMC - PubMed